GBA2 and nasopharyngeal carcinoma: To date there is no curative therapy for NPC, and the only approved treatment for NPC is Miglustat, a drug that inhibits Glucosylceramidase Beta 2 (GBA2) and delays the progression of neurological symptoms (Ridley et al., 2013; Lyseng-Williamson, 2014).